Compare Apple Inc (AAPL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apple Inc vs BIO-TECHNE Corp — how do they compare? Apple Inc trades at $304.36 (market cap $4.50T), while BIO-TECHNE Corp trades at $72.16 (market cap $11.24B). The key difference: Apple Inc is far larger — about 400.4× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays the higher dividend (0.44%). Which is the better fit depends on your goals.
| AAPL | TECH | |
|---|---|---|
Market Cap | $4.50T | $11.24B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $340.08 | $72.29 |
52-Week Low | $224.90 | $43.31 |
Enterprise Value | $4.52T | $11.32B |
Dividend Yield | 0.35% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apple's stock trades at $306.2, down 2.28% for the day, with a bearish technical signal and key support at $306. Fundamentally, the company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.02 exceeding the $1.89 estimate, and revenue growth to $416.16 billion in 2025. Recent news highlights institutional buying and AI potential through a partnership with Alphabet's Gemini.
The outlook remains positive with a consensus price target of $337.63, implying upside, supported by robust profitability and cash flow. Risks include weaker iPhone sales forecasts, union disputes, and high valuation multiples. Analyst sentiment is bullish with 63.64% buy ratings, but investors should monitor execution amid competitive and regulatory pressures.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
